Abstract
The following illustrates an actual experience involving allegations of safety problems with the nonsteroidal anti-inflammatory drug (NSAID) Feldene (piroxicam). It is intended to serve as a case study of the ramifications of examining complex issues of risk analysis in a public forum under volatile conditions. Although the safety of the drug was ultimately established, both the process and its conclusion had significant impact on the manufacturer, the regulatory agency, physicians and patients. This discussion will focus particularly on the roles played in this episode by pharmacoepidemiology and the media.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Food and Drug Administration. Center for Drugs and Biologies (1984) Minutes of the Arthritis Advisory Committee meeting, Bethesda, Maryland, October 25–26
Food and Drug Administration. Center for Drugs and Biologies (1985) Minutes of the Arthritis Advisory Committee meeting, Bethesda, Maryland, April 29–30
Ferriman A (1985) “Arthritis Drug Alert After 77 Patients Die”, The Observer, December 22
Letter to Secretary Bowen of the Department of Health and Human Services (1986) from Sidney Wolfe, Director, Health Research Group, January 8.
Transcript of Proceedings, United States of America before the Food and Drug Administration, In the Matter of: Piroxicam (1986) Docket Number 86P-0023, Bethesda, Maryland, February 28
Letter to Sidney M. Wolfe, Director, Health Research Group (1986) from Secretary Bowen of the Department of Health and Human Services, July 7
Pfizer Inc. (1986) Submission on the Petition of Public Citizen Health Research Group regarding Feldene (piroxicam), Food and Drug Administration, Docket Number 86P-0023, March 17
Food and Drug Administration, Center for Drugs and Biologies (1986) Recommendation in Piroxicam Imminent Hazard Proceeding, May 14
Memorandum to Secretary of Health and Human Services Otis Bowen (1986) from Frank E. Young, Commissioner, Food and Drug Administration, May 27
Sachs RM, Bortnichak EA (1986) An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 81 (suppl 5B): 49–55
Weber JCP (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo EP (eds) Advances in Inflammation Research Vol. 6. New York: Raven Press, pages 1–7
FDA (1986) personal communication
Meisel AD (1986) Clinical benefits and comparative safety of piroxicam: analysis of worldwide clinical trials data. Am J Med 81 (suppl 5B): 15–21
Bortnichak EA, Sachs RM (1986) Piroxicam in recent epidemiologic studies. Am J Med 81 (suppl 5B)44–48
Stipp D (1988) “Scientists use medical-record data bases to detect adverse side-effects of drugs”, The Wall Street Journal, March 24, p 33
Beard K, Walker AM, Perera DR, Jick H (1987) Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Intern Med 147: 1621–1623
Carson JL, Strom BL, Soper KA et al. (1987) The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 147: 85–88
Ray WA (1986) Tennessee Medicaid Database Study at Vanderbilt University. Correspondence (February 25 )
Rawson NSB, Inman WHW (1986) Prescription-event monitoring: recent experience with 5 NSAIDs. Med Tox 1 (suppl 1): 79–82
Levy M, Miller DR, Kaufman DW, et al. (1988) Major upper gastrointestinal tract bleeding: relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med 148: 281–285
Sommerville KW, Falkner G, Langman M (1986) Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet I: 462–464
Haglund U, Frost L, Wiholm BE: An evaluation of anti-inflammatory and analgesic drug intake among patients with acute gastrointestinal bleeding (abstr)
Giereksky KE, Revhaug A, Warloe T, et al. (1986) Can the incidence of gastrointestinal hemorrhage caused by drugs be reduced? Tidsskr Nor Laegeforen 106: 662–666
O’Brien JD, Burnham WR (1985) Bleeding from peptic ulcers and use of non-steroidal antiinflammatory drugs in the Romford area. Br Med J 291: 1609–1610
The Pink Sheet (1987) In Brief: “The FDA’s imbroglio”, March 2
Data on file, Pfizer, Inc., New York
Sachs RM, Dieck GS (1987) Industry perspectives and the contributions of pharmacoepidemiology to public health. In: Edlavitch S (ed) Pharmacoepidemiology, Proceedings of the Third International Conference on Pharmacoepidemiology, Minneapolis (in press)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sachs, R.M., Dieck, G.S. (1989). The Feldene Experience: A Case Study. In: Horisberger, B., Dinkel, R. (eds) The Perception and Management of Drug Safety Risks. Health Systems Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74272-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-74272-9_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74274-3
Online ISBN: 978-3-642-74272-9
eBook Packages: Springer Book Archive